Compassionate Use of Tetrabenazine in the Treatment of Abnormal Movements
TBZ
1 other identifier
expanded_access
N/A
0 countries
N/A
Brief Summary
Although the results of studies looking at tetrabenazine have shown its effectiveness in the management of hyperkinetic(too much) movement disorders, it has not been made available in the U.S. The drug must be obtained from Cambridge Laboratories, the distributor, using an individual IND (#16,161). The cost of the drug is passed on to the patient. The purpose of the protocol is to provide an efficacious drug, with few side effects, in an attempt to get rid of a variety of incapacitating dyskinesias (abnormal movements).
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 28, 2007
CompletedFirst Posted
Study publicly available on registry
March 24, 2008
CompletedMarch 24, 2023
March 1, 2023
December 28, 2007
March 22, 2023
Conditions
Keywords
Interventions
25 mg titrated to optimal dose per patient
Eligibility Criteria
You may qualify if:
- Subjects evaluated here at Baylor in the PDCMDC demonstrating need for tetrabenazine treatment.
- Willing to sign informed consent.
- Willing to comply with procedures required as part of this study.
You may not qualify if:
- Those subjects unwilling to comply with study requirements.
- Subjects unable to give informed consent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Joseph Jankoviclead
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- expanded access
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor, Neurology-PDCMDC
Study Record Dates
First Submitted
December 28, 2007
First Posted
March 24, 2008
Last Updated
March 24, 2023
Record last verified: 2023-03